Equities

Zhejiang Ausun Pharmaceutical Co Ltd

603229:SHH

Zhejiang Ausun Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.67
  • Today's Change-0.08 / -1.19%
  • Shares traded2.52m
  • 1 Year change-32.63%
  • Beta0.0497
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,088568599
Total Receivables, Net18218498
Total Inventory365321243
Prepaid expenses3.80194.89
Other current assets, total364576
Total current assets1,6751,1371,021
Property, plant & equipment, net1,059968626
Goodwill, net------
Intangibles, net150154156
Long term investments675033
Note receivable - long term------
Other long term assets0.43----
Total assets2,9522,3151,839
LIABILITIES
Accounts payable301370200
Accrued expenses404332
Notes payable/short-term debt410309267
Current portion long-term debt/capital leases0.879.16--
Other current liabilities, total191431
Total current liabilities771745530
Total long term debt2.047345
Total debt413391312
Deferred income tax2.0713--
Minority interest------
Other liabilities, total35249.46
Total liabilities810854585
SHAREHOLDERS EQUITY
Common stock593402287
Additional paid-in capital677395510
Retained earnings (accumulated deficit)872665459
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.86)(0.91)(1.14)
Total equity2,1421,4611,255
Total liabilities & shareholders' equity2,9522,3151,839
Total common shares outstanding830788788
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.